Central hypothyroidism associated with bexarotene therapy

We report the case of a patient with cutaneous T-cell lymphoma treated by bexaroten Targretin, a synthetic retinoid analog with specific affinity for retinoid X receptor. The treatment induced mixed hyperlipidemia and severe central hypothyroidism characterized by reduced TSH and thyroxine serum levels. Only the pituitary thyreotrope function was affected. Targretin therapy can be maintained. Adverse drug events may be managed by fenofibrate Lipanthyl for dyslipidemia and high dose L-thyroxin Lévothyrox requiring serum free thyroxin level measurement for central hypothyroidism.